Disease/Infection News

RSS

Strativa Pharmaceuticals: Oravig buccal tablets receive FDA approval for OPC

Strativa Pharmaceuticals today announced that the U.S. Food and Drug Administration has approved Oravig (miconazole) buccal tablets for the treatment of oropharyngeal candidiasis, more commonly known as thrush, in adults and children age 16 and older.

17 Apr 2010

FDA approves BioAlliance Pharma's Oravig for OPC

BioAlliance Pharma SA, a company dedicated to the treatment and supportive care of cancer and AIDS patients, announces today the approval by the US FDA of Oravig® (miconazole Lauriad®, known as Loramyc® in Europe) for the treatment of Oropharyngeal Candidiasis (OPC) in adults.

17 Apr 2010

Study: Higher risk of NHL and Cholangiocarcinoma associated with HBV infection

New data presented today at the International Liver CongressTM 2010 found a link between chronic hepatitis B virus and progression to cancers other than hepatocellular carcinoma.

16 Apr 2010

International study evaluates new class of drugs for treating primary biliary cirrhosis

Results of a study presented today at the at the International Liver CongressTM 2010 reveals the effects of a new drug for the treatment of primary biliary cirrhosis, and shows further evaluation is necessary.

16 Apr 2010

Geographic regions with different kinds of birds and mammals could be a source of pathogens

If your home region has a hot, wet climate and a lot of different kinds of birds and mammals living in it, there's a really good chance the region will also contain numerous kinds of pathogens that cause human diseases.

16 Apr 2010

Research shows general health spending offers better return in most affected areas

Eradicating smallpox was one of the greatest human accomplishments of the 20th century, but new research shows initiatives of this kind are not as good a use of health dollars as people might think.

16 Apr 2010

Results of study comparing REMICADE to azathioprine for Crohn's disease published

Findings published today in The New England Journal of Medicine from a first-of-its-kind comparator trial evaluating the anti-tumor necrosis factor (TNF)-alpha biologic treatment REMICADE (infliximab) in the treatment of moderately to severely active Crohn's disease in patients who were naive to immunomodulator and biologic therapy, showed that a significantly greater proportion of patients receiving REMICADE achieved steroid-free remission and mucosal healing compared with patients receiving azathioprine.

16 Apr 2010

UDH to participate in Abbott's new PLEX-ID BPEP

Abbott today announced that the Utah Department of Health is one of five sites in the United States to participate in Abbott's new PLEX-ID Biopreparedness Evaluation Program, which involves Abbott, the Association of Public Health Laboratories and five state public health labs.

16 Apr 2010

Preclinical results of Avila Therapeutics' AVL-181 and AVL-192 presented at EASL Annual Meeting

Avila Therapeutics™, Inc., a biotechnology company developing targeted covalent drugs that treat diseases through protein silencing, presented results of preclinical studies on two of its Hepatitis C Virus protease inhibitors, AVL-181 and AVL-192. These inhibitors, due to their unique mechanism of action with superior selectivity and potency, have potential as best-in-class, pan-genotype HCV therapeutics.

16 Apr 2010

InterMune reports Phase 1b MAD study results of RTV-boosted danoprevir in HCV patients at 45th EASL

InterMune, Inc. today announced results of all three cohorts from a 15-day Phase 1b multiple-ascending-dose (MAD) study of low doses of danoprevir (also known as RG7227 and ITMN-191) boosted by low-dose ritonavir (RTV) in patients chronically infected with hepatitis C virus (HCV) genotype-1.

16 Apr 2010

Findings strengthen promise of SCYNEXIS' SCY-635 for HCV treatment

Drug discovery company SCYNEXIS, Inc. today presented data supporting an impressive resistance profile for SCY-635—a novel, oral cyclophilin inhibitor being studied for the treatment of hepatitis C virus (HCV) infection. In the study, SCYNEXIS demonstrated that the hepatitis C virus required multiple mutations across two separate proteins in order to establish resistance to SCY-635. The majority of HCV drugs on the market and in development require only one targeted viral mutation to establish resistance.

16 Apr 2010

RUCDR is poised to become a world leader in human disease and genome studies

Despite the continuing, crippling effects of a nationwide recession, a genetics research laboratory on Rutgers' Busch Campus is experiencing an economic boom.

16 Apr 2010

Novel instrument may help limit spread of diarrhoea-causing bacteria

New strains of Clostridium difficile are making the diarrhoea-causing bacteria a global health problem. In hospitals especially, the bacteria can be extremely harmful. But a new instrument devised by Professor Chris Probert at The University of Bristol and Norman Ratcliffe from the University of the West of England (UWE) may help limit its spread.

16 Apr 2010

Promising pharmacokinetic data from Idenix Pharmaceuticals' Phase I study of IDX320 for HCV

Idenix Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today reported promising in vitro data for IDX320, an HCV protease inhibitor, demonstrating potent and selective antiviral activity in multiple genotypes, or strains, of the virus.

16 Apr 2010

Seasonal flu tends to move in traveling waves: Researchers

An analysis of hospitalization records for adults age 65 and over found that seasonal flu tends to move in traveling waves, peaking earliest in western states such as Nevada, Utah, and California and working its way east. New England states such as Rhode Island, Maine, and New Hampshire tend to have the latest peak in seasonal flu, according to public health researchers at Tufts University in Boston.

16 Apr 2010

Positive interim data from Idera Pharmaceuticals' Phase 1 trial of IMO-2125 TLR9 agonist presented at 45th EASL

Idera Pharmaceuticals, Inc. announced today that positive interim data from a Phase 1 clinical trial of IMO-2125, a Toll-like Receptor 9 (TLR9) agonist, in null responder patients with chronic hepatitis C virus (HCV) infection were presented at the 45th Annual Meeting of the European Association for the Study of the Liver (EASL).

16 Apr 2010

GeoViz methods help users visualize the pattern of how disease spreads

Disease statistics buried within patient records or detailed in newspaper clippings can be sorted and organized to depict geographic patterns, allowing the discovery of trends that were previously overlooked, according to a Penn State geographer.

16 Apr 2010

Results from Romark Laboratories' STEALTH C-3 clinical trial presented at EASL Annual Meeting

Romark Laboratories announced results from its STEALTH C-3 clinical trial, a phase 2 clinical study of nitazoxanide in treatment-naive patients with genotype 1 chronic hepatitis C. Study results were presented as a late breaking communication at the International Liver Congress™ 2010, the 45th Annual Meeting of the European Association for the Study of the Liver in Vienna, Austria.

16 Apr 2010

Escherichia coli cases drop in 2009

As per a report from the Centers for Disease Control and Prevention (CDC) a 12 % drop in rates of Escherichia coli (E.coli) infection has been noted in 2009 as compared to statistics for 2008. This is being seen by federal health officials as a sign that the new food safety measures are effective. Most of the pathogens under study are from the bacteria family like E.coli 0157, salmonella, campylobacter, listeria and vibrio. It was found that food poisoning rates for the most common pathogens have changed little from statistics collected in 2004.

16 Apr 2010

Idaho Technology receives USASMDC contract to develop flu tests for military personnel

Idaho Technology, Inc. has been awarded a contract by the U.S. Army Space and Missile Defense Command (USASMDC) to develop tests for multiple flu strains on the Joint Biological Agent Identification and Diagnostic System (JBAIDS).

16 Apr 2010

Disease/Infection News

Strativa Pharmaceuticals: Oravig buccal tablets receive FDA approval for OPC

FDA approves BioAlliance Pharma's Oravig for OPC

Study: Higher risk of NHL and Cholangiocarcinoma associated with HBV infection

International study evaluates new class of drugs for treating primary biliary cirrhosis

Geographic regions with different kinds of birds and mammals could be a source of pathogens

Research shows general health spending offers better return in most affected areas

Results of study comparing REMICADE to azathioprine for Crohn's disease published

UDH to participate in Abbott's new PLEX-ID BPEP

Preclinical results of Avila Therapeutics' AVL-181 and AVL-192 presented at EASL Annual Meeting

InterMune reports Phase 1b MAD study results of RTV-boosted danoprevir in HCV patients at 45th EASL

Findings strengthen promise of SCYNEXIS' SCY-635 for HCV treatment

RUCDR is poised to become a world leader in human disease and genome studies

Novel instrument may help limit spread of diarrhoea-causing bacteria

Promising pharmacokinetic data from Idenix Pharmaceuticals' Phase I study of IDX320 for HCV

Seasonal flu tends to move in traveling waves: Researchers

Positive interim data from Idera Pharmaceuticals' Phase 1 trial of IMO-2125 TLR9 agonist presented at 45th EASL

GeoViz methods help users visualize the pattern of how disease spreads

Results from Romark Laboratories' STEALTH C-3 clinical trial presented at EASL Annual Meeting

Escherichia coli cases drop in 2009

Idaho Technology receives USASMDC contract to develop flu tests for military personnel

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Latest News